Supranuclear Ophthalmoplegia Clinical Trials

• Clinical diagnosis of possible or probable PSP Richardson's Syndrome as defined by the 2017 Movement Disorder Society (MDS) criteria.

• Presence of PSP symptoms for ≤5 years at screening (based on the best judgment of the site PI).

• Mini-Mental State Examination (MMSE) score at screening of ≥25.

• Able to walk at least 10 steps with minimal assistance (e.g., one arm for safety, but not postural support).

• Stable doses of permitted medications as described per protocol for 30 days prior to screening.

• Resides at home or in the community (assisted living is acceptable).

• As assessed by the site PI, participant is likely to be able to comply with the protocol for the duration of the study, and has adequate vision, hearing (hearing aid permitted), and literacy (English or Spanish) sufficient for compliance with the required testing procedures.